Success Story: Cancer Immunology Researcher Secures NIW Approval After RFE for Advancing Cancer Treatment

Client’s Testimonial:

 

“I am very grateful to Chen Immigration Law Associates for their excellent support throughout my EB-2 NIW petition. Their team was professional, responsive, and thorough at every stage, particularly in preparing a strong response to the Request for Evidence (RFE). Their expertise and guidance were instrumental in securing my approval. I highly recommend their services to researchers pursuing permanent residency in the United States.”

 


 

On October 13th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Researcher in the Field of Cancer Immunology (Approval Notice).

 


 

General Field: Cancer Immunology

 

Position at the Time of Case Filing: Postdoctoral Researcher

 

Country of Origin: Spain

 

State of Residence at the Time of Filing: New York

 

Approval Notice Date: October 13th, 2026

 

Processing Time: 3 months, 21 days (Premium Processing Upgrade Requested)

 


 

Case Summary:

 

North America Immigration Law Group (Chen Immigration Law Associates) successfully secured I-140 EB-2 National Interest Waiver (NIW) approval after a Request for Evidence (RFE) for a researcher specializing in cancer immunology. The client's work focuses on understanding how the immune system responds to cancer treatments and developing approaches that may improve therapeutic effectiveness.


The client's scholarly achievements provided an important foundation for demonstrating his ability to advance this endeavor. His research record included 4 peer-reviewed journal articles, including 2 first-authored articles, 3 conference abstracts, including 2 first-authored abstracts, and 3 book chapters, including 2 first-authored chapters. His published work had received 86 citations, and he had completed at least 3 peer reviews for scientific journals. These accomplishments demonstrated his experience in conducting original research, communicating scientific findings, and contributing to the evaluation of research within his field.


To establish the significance of his contributions, we presented comparative citation evidence showing that one of his publications ranked among the top 1% most-cited articles and another among the top 10% in their respective field and publication years. Rather than treating citation totals as independently sufficient, we explained how these rankings provided a meaningful comparison of his research influence. We also highlighted examples of independent researchers using the client's findings to investigate cancer treatment responses, develop combined therapeutic approaches, and better understand biological mechanisms affecting treatment effectiveness. These examples demonstrated how his research had contributed to subsequent scientific investigations.


Our petition further connected the client's research experience and future plans to broader U.S. healthcare priorities. By emphasizing the potential of his work to improve cancer treatment strategies and address therapeutic resistance, we demonstrated its substantial merit and national importance. His academic qualifications, scholarly contributions, independent research recognition, and peer-review activities also supported the argument that he was well positioned to continue advancing the proposed endeavor.


Following the issuance of an RFE, the client's I-140 NIW petition was ultimately approved. The case illustrates how a comprehensive presentation of research accomplishments and their broader significance can support eligibility under the Matter of Dhanasar framework. This approval enables the client to continue pursuing research aimed at improving cancer treatment effectiveness and advancing cancer immunology in the United States.